European Commission Unconditionally Approves Pfizer's $43 Billion Acquisition of Seagen

On the 19th, the acquisition of Seagen, a cancer drug manufacturer, by Pfizer, an American pharmaceutical company, for $43 billion was unconditionally approved by the EU's antitrust authority. The European Commission stated that the proposed merger would not raise competition concerns nor have a negative impact on treatment prices. (Jiemian)Original Link